Jazz Pharmaceuticals
🇮🇪 NASDAQ:JAZZ
•
Dec 31, 2024
Jazz Pharmaceuticals Q4 2024 Earnings Report
Jazz Pharmaceuticals reported record revenue and earnings growth in Q4 2024.
Key Takeaways
Jazz Pharmaceuticals delivered strong financial results in Q4 2024 with record revenue of $1.1 billion, driven by growth in key products like Xywav and Epidiolex. The company's net income and non-GAAP adjusted EPS increased significantly compared to the previous year.
Total revenue increased by 8% to $1.1 billion.
GAAP net income rose to $191.1 million, up from $94.2 million in Q4 2023.
Non-GAAP adjusted EPS increased to $6.60 from $5.02 in Q4 2023.
Strong performance driven by key products Xywav and Epidiolex.
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals EPS
Jazz Pharmaceuticals Revenue by Segment
Jazz Pharmaceuticals Revenue by Geographic Location
Forward Guidance
Jazz Pharmaceuticals expects continued revenue growth in 2025, driven by key products and pipeline advancements.
Positive Outlook
- Total revenue guidance between $4.15 billion and $4.40 billion.
- Continued growth in key products Xywav and Epidiolex.
- Advancements in oncology pipeline including Zepzelca.
- Focus on disciplined capital allocation.
- New product launches expected to drive additional revenue.
Challenges Ahead
- Potential pricing pressures in key markets.
- Increased competition in sleep and oncology segments.
- Higher expected R&D expenses due to clinical trials.
- Continued impact of foreign exchange fluctuations.
- Potential supply chain disruptions affecting production.
Revenue & Expenses
Visualization of income flow from segment revenue to net income